MSTN and Duchenne muscular dystrophy: In the phase 2 study of the myostatin inhibitor ACE-031, ambulatory boys with DMD experienced nominal increases in lean mass %CFB at Day 99 in both ACE-031 cohorts (+ 3.6% and + 4.1%; p < 0.05 for each) and placebo (+ 2.6%)34.